BETA
Israeli medical device manufacturer commercializing adjustable neurovascular devices for clot retrieval, aneurysm coiling support and vascular access.
Rapid Medical is a medical device manufacturer founded in 2008 and headquartered in Yokneam, Israel, with U.S. operations in Southlake, Texas. Co-founder and CEO Ronen Eckhouse leads the company’s development and commercialization of interventional neurovascular devices.
Its portfolio centers on TIGERTRIEVER adjustable clot retrievers, COMANECI temporary embolization-assist devices and DRIVEWIRE steerable guidewires. The company uses proprietary manufacturing and braiding techniques to give physicians control over device shape and expansion during endovascular procedures.
Rapid Medical serves ischemic-stroke and intracranial-aneurysm procedures, alongside vascular-access applications. It is also studying distal and medium-vessel stroke treatment through the DISTALS program, extending its clinical research beyond established commercial indications.
TIGERTRIEVER and DRIVEWIRE have FDA 510(k) clearances, while COMANECI received De Novo authorization under DEN170064 on April 24, 2019. Recent decisions include TIGERTRIEVER 25 on March 12, 2026 and DRIVEWIRE 35 on July 17, 2026. DRIVEWIRE 35 is indicated for general intravascular use, including neurovascular and peripheral vessels, to facilitate catheter placement; it is not intended for coronary arteries. [13][10][11]
Rapid Medical is evaluating TIGERTRIEVER 13 for distal and medium-vessel stroke through the DISTALS clinical program. The company states that DMVO use is not indicated in all markets; trial findings are distinct from the indications of each cleared device configuration. [18][7]
Latest recorded source review: 2026-11-01.
Scope: selected product families.
Documented commercial product families.
Operator-adjustable, radiopaque clot-retrieval devices for ischemic stroke intervention. The mesh can be expanded and relaxed during the procedure to adapt to vessel anatomy and engage thrombus. Multiple sizes and configurations are available; use depends on the applicable indication. [6][7][10][9][12][5][3]
Commercially available · FDA-cleared configurations
Temporary adjustable mesh used to support coil embolization of wide-neck intracranial aneurysms. It provides a non-occlusive scaffold during coiling and is removed at the end of the procedure rather than left as a permanent stent. [13][2]
Commercially available · De Novo authorized
Guidewire family with remotely adjustable tip geometry to support navigation and selective catheter placement. DRIVEWIRE 24 and 35 configurations serve neurovascular and peripheral access; the devices are not intended for coronary arteries. [11][4][8][1]
Commercially available · FDA-cleared configurationsFDA cleared DRIVEWIRE35 under K254006 for neurovascular and peripheral intravascular use. [11]
Rapid Medical announced a completed Series D financing led by MicroPort. [14]
FDA granted DEN170064 for Comaneci, Comaneci Petit and Comaneci17. [13]
Accessed 11/01/2026
Last substantive review: 11/1/2026